Preliminary applications will only be accepted until January 18, 2016. If you plan to submit a PAR-15-297 grant application this cycle, an approved preliminary grant application is required. Please note that this has changed from previous application cycles.

Information is available regarding the PLCO trial and PLCO biospecimens.

Please visit the PAR Preliminary Application for Biospecimens and Funding page to preview instructions about the process, review the EEMS Policies and Procedures, and begin a PAR Preliminary Application for Biospecimens and Funding.

Due to administrative factors, the timeline for this review cycle may be subject to change. If you have any questions, please contact CDAS staff at cdas-eems@imsweb.com.

CDAS has been redesigned to incorporate an improved user interface and several new features. Start a new project or click on My Projects in the upper right corner to see a list of the projects you already have access to. Contact Us if you have any questions navigating the new site.

Preliminary applications will only be accepted from approximately December 1, 2015, through January 18, 2016.If you plan to submit a grant application this cycle, an approved preliminary grant application is required. Please note that this has changed from previous application cycles. Once your preliminary grant application has been approved, you will receive a confirmation letter to accompany your grant application.

Information is available regarding the PLCO trial and biospecimens.

Due to administrative factors and uncertainty in website development, the timeline for the release of the preliminary application and upcoming review cycle will be subject to changes. Please check CDAS frequently for an updated timeline. If you have any questions, please contact CDAS staff at cdas-eems@imsweb.com.

Preliminary applications for PLCO EEMS Round 21 will only be accepted from approximately December 1, 2015, through January 3, 2016. If you plan to submit an EEMS application this cycle, an approved preliminary application is required. Please note that this has changed from previous application cycles. Once your preliminary application has been approved, you will be notified and you will be able to continue and submit a full application. The deadline for full application submission is March 1, 2016.

Information is available regarding the PLCO trial and biospecimens.

Due to administrative factors and uncertainty in website development, the timeline for the release of the preliminary application and upcoming review cycle will be subject to changes. Please check CDAS frequently for an updated timeline. If you have any questions, please contact CDAS staff at cdas-eems@imsweb.com.

New PLCO cancer data added. Data version: may14.d052114

• New Inadequate FSG variables:
  • The variables fsgin0/3/5/35 were removed from the colon person file.
  • The new variable fsg_in was added to the screening file, and the variables fsg_in0/3/5/35 were added to the person file. See documentation for variable formats.
• New Hematopoetic Cancer Type variable:
  • The variable hema_type was given a new format in the hema_prsn file. See documentation for variable formats.
  • The variable hema_subtype has been dropped.
• New SCU Complications variable indicating whether or not a complication was added from the SCU data.
• Hematopoietic Non-target Misc Cancers:
  • Cancers with ICD codes classified as Non-Hodgkins Lymphoma, myeloproliferative disease, or myelodysplastic syndrome have been improved by classifying them as confirmed borderline hematopoietic cancers.

New PLCO ancillary study data added:

• Study of Colonoscopy Utiliization (SCU)

New PLCO lab data added:

• Vitamin D

The total PLCO population now has 154,898 participants. Over the course of the trial this number decreases due to participants withdrawing, improper consent at randomization or duplication at randomization.